OOIR: Observatory of International Research

Papers

(The H4-Index of Expert Opinion on Drug Discovery is 27. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)

Article	Citations
Lessons learned from phenotypic drug discovery efforts	168
γ-Secretase: once and future drug target for Alzheimer’s disease	141
Advances in the discovery of drugs that treat pulmonary arterial hypertension	103
Advances in ion channel high throughput screening: where are we in 2023?	83
Reality check: lipid-oligonucleotide conjugates for therapeutic applications	65
Discovery of novel cathepsin K inhibitors for osteoporosis treatment using a deep learning-based strategy	60
Scaffold hopping approaches for dual-target antitumor drug discovery: opportunities and challenges	43
Strategies for targeting RNA with small molecule drugs	41
Polypharmacology prediction: the long road toward comprehensively anticipating small-molecule selectivity to de-risk drug discovery	40
A comprehensive update on the use of molecular topology applications for anti-infective drug discovery	39
What is the plausibility that all drugs will be designed by computers by the end of the decade?	39
Tools and techniques for the discovery of therapeutic aptamers: recent advances	38
Bisquinoline as a promising scaffold in anti-infective drug discovery: the current state of the art and future prospects	36
The preclinical discovery and development of gepirone hydrochloride extended-release tablets: the first oral selective 5-HT1A receptor agonist for the treatment of major depressive disorder	36
Methods in marine natural product drug discovery: what’s new?	35
Designing drugs against leishmaniasis: is targeting the sterol biosynthesis pathway the answer?	34
Understanding the impact of binding free energy and kinetics calculations in modern drug discovery	33
A cautionary tale of paradox and false positives in cannabidiol research	32
Phenotypic screening for new heart failure therapeutics: scalable animal modeling in zebrafish	32
The rules often neglected in current medicinal chemistry	32
The potential of microfluidic platforms for neuron differentiation and pain modeling in novel drug discovery	32
Calcium channel blockers’ contribution to overcoming Current drug discovery challenges in Alzheimer’s disease	30
An update on knowledge graphs and their current and potential applications in drug discovery	29
Virtual screening: hope, hype, and the fine line in between	28
Acoustic ejection mass spectrometry: fundamentals and applications in high-throughput drug discovery	28

C. elegans : a prominent platform for modeling and drug screening in neurological disorders	28
Water in drug design: pitfalls and good practices	28
Novel insights into structure–activity relationships of kynurenine 3-monooxygenase inhibitors (KMOis) with emphasis on chemical space, activity landscape exploration	27